Biliary Tract Cancer disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: BLR013 MIFTS: 52	Biliary Tract Cancer Categories: Cancer diseases, Gastrointestinal diseases, Liver diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Biliary Tract Cancer

MalaCards integrated aliases for Biliary Tract Cancer:

Name: Biliary Tract Cancer ¹¹ ¹⁹ ⁷⁵ ⁵³ ¹⁴ ⁷⁵

Malignant Tumour of Biliary Tract ¹¹

Biliary Tract Neoplasms ⁴³

Biliary Tract Neoplasm ¹⁶

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Gastrointestinal diseases Liver diseases

See all MalaCards categories (disease lists)

ICD10: ³¹

Neoplasms

Malignant neoplasms of digestive organs

Malignant neoplasm of other and unspecified parts of biliary tract

Malignant neoplasm: Biliary tract, unspecified

External Ids:

Disease Ontology ¹¹ DOID:4607

ICD9CM ³⁴ 156.9

MeSH ⁴³ D001661

SNOMED-CT ⁶⁸ 126853008 93688006

ICD10 ³¹ C24.9

EFO ¹⁶ EFO_0003891

UMLS ⁷¹ C0005426 C0750952

Sources

Summaries for Biliary Tract Cancer

Disease Ontology: ¹¹ A hepatobiliary system cancer that results in malignant growth located in the gallbladder or located in the bile duct.

MalaCards based summary: Biliary Tract Cancer, also known as malignant tumour of biliary tract, is related to cholangiocarcinoma and gallbladder cancer. An important gene associated with Biliary Tract Cancer is SMAD4 (SMAD Family Member 4), and among its related pathways/superpathways are Signal Transduction and GPCR Pathway. The drugs Gemcitabine and Capecitabine have been mentioned in the context of this disorder. Affiliated tissues include gallbladder, bile duct and lymph node, and related phenotypes are Decreased viability with paclitaxel and Increased cell viability after pRB stimulation

Wikipedia: ⁷⁵ Cholangiocarcinoma, also known as bile duct cancer, is a type of cancer that forms in the bile ducts.... more...

Sources

Related Diseases for Biliary Tract Cancer

Diseases related to Biliary Tract Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 422)

#	Related Disease	Score	Top Affiliating Genes
1	cholangiocarcinoma	32.8	SMAD4 PTGS2 MUC5AC MUC4 MTOR MIR21
2	gallbladder cancer	32.7	TGFBR2 SMAD4 MUC5AC MLH1 MIR17 MIR145
3	bile duct cancer	32.7	SMAD4 MUC5AC MUC4 MIR21 MIR17 MIR145
4	intrahepatic cholangiocarcinoma	32.1	MUC4 MIR17 ERBB2 EGFR
5	ampulla of vater cancer	31.8	SMAD4 MUC5AC MLH1 MIR145 ERBB2 EGFR
6	gallbladder disease	31.6	MIR17 MIR145 MIR143 IL6 ERBB2 EGFR
7	exanthem	31.6	MTOR IL6 ERBB2 EGFR
8	thrombocytopenia	31.5	SMAD4 RUNX3 MIR21 IL6 HDAC9 ERBB2
9	cholecystitis	31.3	MUC5AC MUC4 EGFR
10	biliary tract disease	31.3	MUC5AC MIR21 MIR17 MIR145 MIR143 IL6
11	breast ductal carcinoma	31.3	TGFBR2 SMAD4 MUC5AC MET ERBB2 EGFR
12	adenocarcinoma	31.2	TGFBR2 SMAD4 PTGS2 MUC5AC MUC4 MLH1
13	peripheral nervous system disease	31.1	PTGS2 MTOR MIR21 MIR17 MIR145 MIR143
14	pancreatic ductal adenocarcinoma	31.1	SMAD4 MIR21 MIR17 MIR145 MIR143
15	hepatocellular carcinoma	31.0	TGFBR2 SMAD4 RUNX3 PTGS2 MUC4 MTOR
16	bladder cancer	31.0	PTGS2 MTOR MLH1 MIR21 MIR17 MIR145
17	pancreatic cancer	31.0	TGFBR2 SMAD4 RUNX3 PTGS2 MUC5AC MUC4
18	pancreatic adenocarcinoma	31.0	TGFBR2 SMAD4 PTGS2 MUC4 MTOR MET
19	diabetes mellitus	30.8	PTGS2 MTOR MIR21 MIR17 MIR145 MIR143
20	lynch syndrome	30.8	TGFBR2 SMAD4 RUNX3 PTGS2 MLH1 MIR17
21	pancreatic ductal carcinoma	30.7	SMAD4 MUC5AC ERBB2 EGFR
22	stomatitis	30.7	MTOR IL6 DPYD
23	duodenum adenocarcinoma	30.7	SMAD4 MUC5AC MLH1
24	gastroesophageal adenocarcinoma	30.7	MET ERBB2 EGFR
25	ampulla of vater adenocarcinoma	30.7	SMAD4 MUC5AC MIR145
26	adenoma	30.7	TGFBR2 SMAD4 PTGS2 MUC5AC MLH1
27	peptic ulcer disease	30.6	PTGS2 MUC5AC IL6
28	gastric ulcer	30.6	PTGS2 MET IL6
29	inherited cancer-predisposing syndrome	30.6	SMAD4 MLH1 MET EGFR
30	bap1 tumor predisposition syndrome	30.6	SMAD4 MLH1 MET EGFR
31	hereditary breast ovarian cancer syndrome	30.6	SMAD4 MLH1 ERBB2 EGFR
32	gastric adenocarcinoma	30.6	SMAD4 PTGS2 MUC4 MTOR MLH1 MET
33	gastrointestinal stromal tumor	30.6	MTOR MET ERBB2 EGFR
34	bile duct disease	30.6	MIR21 MIR17 MIR145 MIR143 IL6
35	esophagitis	30.5	PTGS2 IL6 EGFR
36	respiratory failure	30.5	MUC5AC MIR21 MIR17 IL6
37	ovarian cancer	30.3	TGFBR2 SMAD4 PTGS2 MUC5AC MUC4 MTOR
38	breast cancer	30.2	TGFBR2 SMAD4 RUNX3 PTGS2 MTOR MLH1
39	gastric cancer	30.2	TGFBR2 SMAD4 RUNX3 PTGS2 MUC5AC MUC4
40	carcinoma of gallbladder and extrahepatic biliary tract	11.1
41	neutropenia	10.9
42	factor vii deficiency	10.8
43	gallbladder disease 1	10.7
44	cholangitis	10.6
45	klatskin's tumor	10.6
46	signet ring cell adenocarcinoma	10.5	MUC5AC MLH1 ERBB2
47	paronychia	10.5	MTOR ERBB2 EGFR
48	small intestine adenocarcinoma	10.5	SMAD4 MUC5AC MLH1
49	pancreatic signet ring cell adenocarcinoma	10.5	MUC5AC MUC4 MLH1
50	gastroesophageal junction adenocarcinoma	10.5	MET ERBB2 EGFR

Graphical network of the top 20 diseases related to Biliary Tract Cancer:

Sources

Symptoms & Phenotypes for Biliary Tract Cancer

GenomeRNAi Phenotypes related to Biliary Tract Cancer according to GeneCards Suite gene sharing:

²⁵

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased viability with paclitaxel	GR00179-A-1	9.35	EGFR MTOR
2	Decreased viability with paclitaxel	GR00179-A-2	9.35	MTOR
3	Decreased viability with paclitaxel	GR00179-A-3	9.35	EGFR MTOR
4	Increased cell viability after pRB stimulation	GR00230-A-1	8.92	EGFR ERBB2 MET TGFBR2

MGI Mouse Phenotypes related to Biliary Tract Cancer:

⁴⁵ (show all 15)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.35	EGFR ERBB2 IL6 LGR4 MET MIR143
2	growth/size/body region	MP:0005378	10.3	EGFR ERBB2 HDAC9 IL6 LGR4 MET
3	muscle	MP:0005369	10.26	EGFR ERBB2 HDAC9 IL6 MET MIR145
4	endocrine/exocrine gland	MP:0005379	10.21	EGFR ERBB2 IL6 LGR4 MET MLH1
5	neoplasm	MP:0002006	10.2	EGFR ERBB2 IL6 MET MLH1 MUC4
6	digestive/alimentary	MP:0005381	10.18	DPYD EGFR ERBB2 IL6 LGR4 MET
7	renal/urinary system	MP:0005367	10.14	EGFR IL6 LGR4 MET MTOR PTGS2
8	cardiovascular system	MP:0005385	10.13	EGFR ERBB2 HDAC9 IL6 LGR4 MET
9	liver/biliary system	MP:0005370	10.11	EGFR IL6 LGR4 MET MTAP PTGS2
10	immune system	MP:0005387	10.07	EGFR IL6 LGR4 MET MLH1 MTAP
11	embryo	MP:0005380	10.06	EGFR ERBB2 LGR4 MET MTAP MTOR
12	adipose tissue	MP:0005375	10.04	EGFR IL6 LGR4 MTOR PTGS2 RUNX3
13	respiratory system	MP:0005388	9.9	EGFR ERBB2 IL6 MET MLH1 MTAP
14	mortality/aging	MP:0010768	9.83	EGFR ERBB2 HDAC9 IL6 LGR4 MET
15	integument	MP:0010771	9.32	EGFR ERBB2 IL6 LGR4 MLH1 MTAP

Sources

Drugs & Therapeutics for Biliary Tract Cancer

Drugs for Biliary Tract Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 135)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Gemcitabine

Approved

Phase 3

95058-81-4, 122111-03-9

60750

Capecitabine

Approved, Investigational

Phase 3

154361-50-9

60953

Oxaliplatin

Approved, Investigational

Phase 3

61825-94-3

43805 11947679 6857599

Magnesium sulfate

Approved, Investigational, Vet_approved

Phase 3

7487-88-9

Durvalumab

Approved, Investigational

Phase 3

1428935-60-7

Cisplatin

Approved

Phase 3

15663-27-1

2767 5702198 441203

Trastuzumab

Approved, Investigational

Phase 3

180288-69-1

Paclitaxel

Approved, Vet_approved

Phase 2, Phase 3

33069-62-4

36314

Niraparib

Approved, Investigational

Phase 3

1038915-60-4

24958200

Futibatinib

Approved, Investigational

Phase 3

1448169-71-8

71621331

Ivosidenib

Approved, Investigational

Phase 3

1448347-49-6

78140854 71657455

Levoleucovorin

Approved, Experimental, Investigational

Phase 3

68538-85-2, 58-05-9, 73951-54-9

149436 6006

Fluorouracil

Approved

Phase 3

51-21-8

3385

Folic acid

Approved, Nutraceutical, Vet_approved

Phase 3

59-30-3

6037

Cediranib

Investigational

Phase 2, Phase 3

288383-20-0

9933475

Antiemetics

Phase 3

Emetics

Phase 3

Antiviral Agents

Phase 3

Anti-Infective Agents

Phase 3

Mitogens

Phase 2, Phase 3

Antineoplastic Agents, Immunological

Phase 3

Albumin-Bound Paclitaxel

Phase 2, Phase 3

Poly(ADP-ribose) Polymerase Inhibitors

Phase 3

Antimetabolites

Phase 3

Immunosuppressive Agents

Phase 3

Immunologic Factors

Phase 3

Vitamins

Phase 3

Folate

Phase 3

Vitamin B9

Phase 3

Trace Elements

Phase 3

Vitamin B Complex

Phase 3

Antidotes

Phase 3

Micronutrients

Phase 3

Protective Agents

Phase 3

Racepinephrine

Approved, Vet_approved

Phase 2

51-43-4, 329-65-7

838 5816

Ropivacaine

Approved

Phase 2

84057-95-4

71273 175805

Fentanyl

Approved, Illicit, Investigational, Vet_approved

Phase 2

437-38-7

3345

Oxycodone

Approved, Illicit, Investigational

Phase 2

76-42-6

5284603

Morphine

Approved, Investigational

Phase 2

57-27-2

5288826

Cetuximab

Approved

Phase 2

205923-56-4

Mitomycin

Approved

Phase 2

50-07-7

5746

Panitumumab

Approved, Investigational

Phase 2

339177-26-3

Sargramostim

Approved, Investigational

Phase 2

123774-72-1

Olaparib

Approved

Phase 2

763113-22-0

23725625

Erlotinib

Approved, Investigational

Phase 2

183319-69-9, 183321-74-6

176870

Adenosine

Approved, Investigational

Phase 2

58-61-7

60961

Fludarabine

Approved

Phase 2

75607-67-9, 21679-14-1

30751 657237

Aldesleukin

Approved

Phase 2

110942-02-4

Cyclophosphamide

Approved, Investigational

Phase 2

50-18-0, 6055-19-2

2907

Pemetrexed

Approved, Investigational

Phase 2

150399-23-8, 137281-23-3

60843 446556 135565230

Interventional clinical trials:

(show top 50) (show all 297)

#	Name	Status	NCT ID	Phase	Drugs
1	The Effect of Individualized Precision Therapy Programs in Patients With Biliary Tract Cancer	Unknown status	NCT02943031	Phase 4
2	RCT Steel (Wallstent®) vs Nitinol (Wallflex®) Bile Duct Stent for Palliation of Malignant Obstruction	Completed	NCT00980889	Phase 4
3	Re-intervention for Occluded Biliary Metal Stent in Malignant Distal Bile Duct Obstruction: a Prospective Randomized Multi-center Trial Comparing Covered and Uncovered Metal Stent	Completed	NCT01315522	Phase 4
4	Endoscopic Radiofrequency Ablation for Malignant Biliary Obstruction	Completed	NCT01758341	Phase 4
5	A Randomized, Open, Multi-center Phase IIb/III Clinical Study to Assess the Efficacy and Safety of Surufatinib Compared to Capecitabine in Advanced or Metastatic Biliary Tract Carcinoma (BTC) Patients	Unknown status	NCT03873532	Phase 2, Phase 3	Surufatinib;Capecitabine
6	A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Varlitinib Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract Cancer as Second Line Systemic Therapy	Completed	NCT03093870	Phase 2, Phase 3	Varlitinib;Capecitabine;Placebo (for Varlitinib)
7	A Randomised Clinical Trial Evaluating Adjuvant Chemotherapy With Capecitabine Compared to Expectant Treatment Alone (Observation) Following Surgery for Biliary Tract Cancer	Completed	NCT00363584	Phase 3	capecitabine
8	Randomized Phase III Trial Comparing Gemcitabine/Cisplatin/S-1 With Gemcitabine/Cisplatin for Unresectable Biliary Tract Cancer	Completed	NCT02182778	Phase 3	Gemcitabine/Cisplatin;Gemcitabine/Cisplatin /S-1
9	A Phase III, Randomised, Multicentre Open-label Study of Active Symptom Control (ASC) Alone or ASC With Oxaliplatin/ 5F-U Chemotherapy for Patients With Locally Advanced/ Metastatic Biliary Tract Cancers Previously Treated With Cisplatin/ Gemcitabine Chemotherapy.	Completed	NCT01926236	Phase 3	L-folinic acid;5 FU;Oxaliplatin
10	Evaluation of Effects of Early Palliative Care on Quality of Life of Advanced Cancer Patients. A Multicenter Controlled Randomised Clinical Trial	Completed	NCT02988635	Phase 3
11	Randomised Phase II Trial of Cediranib (AZD2171) Versus Placebo in Addition to Cisplatin/Gemcitabine Chemotherapy for Patients With Advanced Biliary Tract Cancers	Completed	NCT00939848	Phase 2, Phase 3	gemcitabine;cisplatin;Placebo;cediranib
12	A Prospective Randomized Clinical Trial of Two Surgical Techniques for Pancreaticojejunostomy in Patients Undergoing Pancreaticoduodenectomy: Nonstented Stump-closed vs Duct-to-Mucosa Pancreaticojejunostomy	Completed	NCT01731821	Phase 3
13	Adjuvant Chemotherapy With Gemcitabine and Capecitabine Compared to Capecitabine for Biliary Tract Cancer After Curative Resection	Recruiting	NCT03779035	Phase 3	Gemcitabine;Capecitabine
14	A Randomized, Multi-center Phase III Trial of Adjuvant Chemotherapy With Gemcitabine and Capecitabine Compared to Capecitabine Alone in Curatively Resected Biliary Tract Cancer	Recruiting	NCT04401709	Phase 3	Gemcitabine/Capecitabine;Capecitabine
15	Gemcitabine and Oxaliplatin With or Without KN035 for Biliary Tract Cancer: a Randomised, Open-label, Parallel-group, Multicenter Phase III Study	Recruiting	NCT03478488	Phase 3	KN035 plus Gemcitabine & oxaliplatin;Gemcitabine & oxaliplatin
16	Randomized, Placebo-controlled, Open-label, Phase 2b Clinical Trial to Evaluate the Antitumor Activity of Combination Therapy of SMT-NK and Pembrolizumab vs Pembrolizumab Monotherapy in Patients With Advanced Biliary Tract Cancer	Recruiting	NCT05429697	Phase 2, Phase 3	SMT-NK inj.+Pembrolizumab;Pembrolizumab
17	Neoadjuvant Chemotherapy With Gemcitabine Plus Cisplatin Followed by Radical Liver Resection Versus Immediate Radical Liver Resection Alone With or Without Adjuvant Chemotherapy in Incidentally Detected Gallbladder Carcinoma After Simple Cholecystectomy or in Front of Radical Resection of BTC (ICC/ECC) - A Phase III Study of the German Registry of Incidental Gallbladder Carcinoma Platform (GR) - The AIO/ CALGP/ ACO- GAIN-Trial -	Recruiting	NCT03673072	Phase 3	Gemcitabine;Cisplatin;Adjuvant chemotherapy
18	A Randomized, Open-label, Parallel Controlled, Multi-center Phase III Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Chemotherapy as Second-line Treatment in Subjects With Advanced Biliary Cancer	Recruiting	NCT04809142	Phase 3	TQB2450 Injection;Anlotinib hydrochloride;Oxaliplatin injection;Capecitabine tablets;Gemcitabine hydrochloride injection
19	A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) as First-line Treatment of Biliary Tract Cancer	Active, not recruiting	NCT04066491	Phase 2, Phase 3	M7824;Placebo;Gemcitabine;Cisplatin
20	A Phase III Randomized, Double-Blind Placebo Controlled, Multi-Regional, International Study of Durvalumab in Combination With Gemcitabine Plus Cisplatin Versus Placebo in Combination With Gemcitabine Plus Cisplatin for Patients With First-Line Advanced Biliary Tract Cancers	Active, not recruiting	NCT03875235	Phase 3	Durvalumab;Placebo
21	A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers	Active, not recruiting	NCT03768414	Phase 3	Cisplatin;Gemcitabine Hydrochloride;Nab-paclitaxel
22	Open-Label, Multicenter, Phase II/III Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer After Gemcitabine and Cisplatin-Based Treatment Failure	Not yet recruiting	NCT05065957	Phase 2, Phase 3	D07001-softgel capsules + Xeloda (or TS-1);mFOLFOX
23	An Open, Single-arm Prospective Clinical Study Evaluating the Efficacy of Systemic Venous Gemcitabine-based Chemotherapy Combined With Immunocheckpoint Inhibitors in First-line Treatment of Advanced Biliary Malignancies	Not yet recruiting	NCT05487443	Phase 2, Phase 3	Gemcitabine-based chemotherapy regimen combined with immunocheckpoint inhibitors
24	A Phase 2/3 Randomized, Controlled Study of CTX-009 in Combination With Paclitaxel Versus Paclitaxel Alone in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers Who Have Received One Prior Systemic Chemotherapy Regimen	Not yet recruiting	NCT05506943	Phase 2, Phase 3	CTX-009;Paclitaxel
25	Molecular Targeted Maintenance Therapy Versus Standard of Care in Advanced Biliary Cancer: an International, Randomised, Controlled, Open-label, Platform Phase 3 Trial	Not yet recruiting	NCT05615818	Phase 3	Futibatinib;Ivosidenib;Zanidatamab;Trastuzumab;Neratinib;Encorafenib;Binimetinib;Niraparib;Cisplatin;Gemcitabine
26	A Phase III Open-Label, Multi-Centre, Randomized Study Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Previously Untreated Locally Advanced or Metastatic Biliary Tract Cancer	Terminated	NCT04163900	Phase 3	NUC-1031;Gemcitabine;Cisplatin
27	A Phase 3 Multicenter, Open Label, Randomized Study of XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary Tumors Not Amenable to Conventional Surgery	Terminated	NCT00090025	Phase 3	becatecarin;5-Fluorouracil Plus Leucovorin
28	A Randomized, Open-Label, Comparative, Parallel-Group, Multicenter Study of SPARC1507 in Subjects With Cancer	Withdrawn	NCT02597465	Phase 3	SPARC1507;Reference1507
29	GAMBIT Trial: A Randomized,Non-comparative, Open-label Clinical Trial Evaluating Cisplatin Plus Irinotecan in the Treatment of Gallbladder or Biliary Tract Cancer	Unknown status	NCT01859728	Phase 2	Irinotecan;Cisplatin;Gemcitabine
30	An Exploratory Study to Evaluate Efficacy and Safety of Fruquintinib as Second-line Treatment for Patients With Advanced or Metastatic Biliary Tract Cancer	Unknown status	NCT04156958	Phase 2	Fruquintinib
31	A Multicentre, Open-label Phase II Study of Nab-paclitaxel in Combination With Gemcitabine + Cisplatin as First Line Treatment in Patients With Unresectable Biliary Tract Cancer	Unknown status	NCT02632305	Phase 2	nab-paclitaxel in combination with gemcitabine + cisplatin
32	Anlotinib Hydrochloride in Combination With PD1 With Gemcitabine Plus(+)Cisplatin Compared With Gemcitabine +Cisplatin as First-line Chemotherapy for Unresectable or Metastatic Biliary Tract Cancer: A Randomized, Controlled, Multicenter Phase II Clinical Trial	Unknown status	NCT04300959	Phase 2	Anlotinib Hydrochloride in Combination With PD1 With Gemcitabine Plus(+)Cisplatin;Gemcitabine Plus(+)Cisplatin
33	A Phase II Study for Nab-paclitaxel Plus Cisplatin vs Gemcitabine Plus Cispatin as First Line Chemotherapy in Advanced Biliary Tract Cancer	Unknown status	NCT04692051	Phase 2	Nab-paclitaxel + Cisplatin;Gemcitabine + Cisplatin
34	Phase II Study of Apatinib as Second Line Therapy in Patients With Advanced Refractory Biliary Tract Cancer	Unknown status	NCT03144856	Phase 2	Apatinib
35	A Phase I/II, Open-label, Single-center Study to Evaluate the Safety and Efficacy of the Pan-immunotherapy in Subjects With Local Advanced/Metastatic Biliary Tract Cancer	Unknown status	NCT04004234	Phase 1, Phase 2	Manganese Chloride;nab-paclitaxel;Gemcitabine;anti-PD-1 antibody
36	Phase II Study of S-1 in Combination With Oxaliplatin and Irinotecan in Patients With Advanced, Recurrent or Metastatic Biliary Tract Cancer	Unknown status	NCT02527824	Phase 2	Oxaliplatin, Irinotecan, S-1
37	Toripalimab Combined With S1 and Albumin Paclitaxel as First Line in Patients With Advanced Biliary Tract Cancer: a Single-arm,One Center， Phase II Clinical Study	Unknown status	NCT04027764	Phase 2	Toripalimab Combined With S1 and Albumin Paclitaxel
38	Phase II Randomized Trial of S-1, Leucovorin, Oxaliplatin and Gemcitabine (SLOG) vs Gemcitabine and Cisplatin (GC) in Locally Advanced or Metastatic Biliary Tract Cancer	Unknown status	NCT03406299	Phase 2	Tegafur;Leucovorin;Oxaliplatin;Gemcitabine;Cisplatin
39	A Multicenter, Phase I-II Trial of Gemcitabine Plus Oxaliplatin and Nab-paclitaxel in Subjects With Advanced (Unresectable or Metastatic) Biliary Tract Cancer	Unknown status	NCT03943043	Phase 1, Phase 2	nab-paclitaxel
40	Multicenter Phase II Study of Docetaxel and Oxaliplatin Combination in Patients With Locally Advanced or Metastatic Biliary Tract Cancer	Unknown status	NCT01234051	Phase 2	Docetaxel, Oxaliplatin
41	An Pilot Study of S-1 Combined With Oxaliplatin for First-line Treatment of Unresectable, Metastatic or Locally Advanced Biliary Tract Cancer or Ampullary Adenocarcinoma	Unknown status	NCT01180153	Phase 2	S-1 oxaliplatin
42	Multicenter Phase II Study of Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) in Patients With Locally Advanced or Metastatic Biliary Tract Cancer	Unknown status	NCT01494363	Phase 2	Fluorouracil;Leucovorin;Oxaliplatin;Irinotecan
43	A Pilot Study of PD-1 Inhibitor in Combination With Gemcitabine/Cisplatin for Patients With Advanced Unresectable or Metastatic Biliary Tract Cancers	Unknown status	NCT03311789	Phase 1, Phase 2	PD-1 inhibitor + Gemcitabine + Cisplatin
44	Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers: a Single-arm, Non-randomized, Single-center Clinical Trial and Biomarker Study	Unknown status	NCT04211168	Phase 2	Toripalimab plus Lenvatinib
45	A Phase 2 Study of Pyrotinib in Patients With Advanced/ Metastatic HER2-Altered Biliary Tract Cancers Who Have Failed One or Two Prior Lines of Therapies	Unknown status	NCT04571710	Phase 2	SHR1258
46	Multicenter, Phase II Study of Chemotherapy in Combination With Trastuzumab in Patients of Pretreated, HER2 Positive, Relapse or Metastatic Carcinoma of Digestive System	Unknown status	NCT03185988	Phase 2	chemotherapy in combination with trastuzumab for arm1;chemotherapy in combination with trastuzumab for arm2;chemotherapy in combination with trastuzumab for arm3;chemotherapy in combination with trastuzumab for arm4
47	Phase II Study of Second Line Capecitabine Plus Oxaliplatin (XELOX) in Patients With Advanced Biliary Tract Carcinoma After Failure of Gemcitabine-based Chemotherapy	Unknown status	NCT02350686	Phase 2	capecitabine;oxaliplatin
48	Phase II Exploratory Study of S-1 Combined With Oxaliplatin Sequential S-1 Single-agent First-line Treatment of Unresectable Metastatic or Locally Advanced Biliary System, Periampullary Cancer and Pancreatic Cancer	Unknown status	NCT01811277	Phase 2	SOX sequential S-1
49	A Multicenter Phase II Trial of Preoperative Chemotherapy With Gemcitabine/ Cisplatin /S-1 (GCS) for Biliary Tract Cancers With Lymph Node Metastasis Diagnosed by Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)	Unknown status	NCT01821248	Phase 2	Gemcitabine, Cisplatin, S-1
50	Comparison of Analgesic Efficacy After Major Surgery in Pancreatobiliary Cancers: Intravenous Patient-controlled Analgesia Versus Patient-controlled Epidural Analgesia	Unknown status	NCT04352023	Phase 2

Search NIH Clinical Center for Biliary Tract Cancer

Cochrane evidence based reviews: biliary tract neoplasms

Sources

Genetic Tests for Biliary Tract Cancer

Sources

Anatomical Context for Biliary Tract Cancer

Organs/tissues related to Biliary Tract Cancer:

FMA: Gallbladder, Bile Duct

MalaCards : Lymph Node, Skin, Liver, Pancreas, T Cells, Lung, Breast

Sources

Publications for Biliary Tract Cancer

Articles related to Biliary Tract Cancer:

(show top 50) (show all 1780)

#	Title	Authors	PMID	Year
1	EGFR and HER2 expression in advanced biliary tract cancer. ⁵³ ⁶²	Harder J...Opitz OG	19777609	2009
2	Simultaneous blockade of the epidermal growth factor receptor/mammalian target of rapamycin pathway by epidermal growth factor receptor inhibitors and rapamycin results in reduced cell growth and survival in biliary tract cancer cells. ⁵³ ⁶²	Herberger B...Filipits M	19509244	2009
3	Thymidylate synthase and dihydropyrimidine dehydrogenase are upregulated in pancreatic and biliary tract cancers. ⁵³ ⁶²	Shimoda M...Kubota K	19571608	2009
4	MUC4 and MUC5AC are highly specific tumour-associated mucins in biliary tract cancer. ⁵³ ⁶²	Matull WR...Pereira SP	18475301	2008
5	[Expressions and clinical significances of c-met, c-erbB-2, COX-2, and IL-6 in the biliary tract cancers]. ⁵³ ⁶²	Joo HH...Choi YK	18159174	2007
6	A randomised phase II study of OSI-7904L versus 5-fluorouracil (FU)/leucovorin (LV) as first-line treatment in patients with advanced biliary cancers. ⁵³ ⁶²	Ciuleanu T...Philip PA	17364234	2007
7	Restoration of RUNX3 enhances transforming growth factor-beta-dependent p21 expression in a biliary tract cancer cell line. ⁵³ ⁶²	Hasegawa K...Chiba T	17470130	2007
8	CPT-11 (SN-38) chemotherapy may be selectively applicable to biliary tract cancer with low hMLH1 expression. ⁵³ ⁶²	Sato K...Miyazaki K	17465213	2007
9	Deficient expression of the DPD gene is caused by epigenetic modification in biliary tract cancer cells, and induces high sensitivity to 5-FU treatment. ⁵³ ⁶²	Sato K...Miyazaki K	16820886	2006
10	Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib. ⁵³ ⁶²	Wiedmann M...Caca K	16926628	2006
11	K-ras mutation, p53 overexpression, and microsatellite instability in biliary tract cancers: a population-based study in China. ⁵³ ⁶²	Rashid A...Hsing AW	12374683	2002
12	Allelotype analysis of the PTEN, Smad4 and DCC genes in biliary tract cancer. ⁵³ ⁶²	Suto T...Nakamura S	12168833	2002
13	Infrequent microsatellite instability in biliary tract cancer. ⁵³ ⁶²	Suto T...Nakamura S	11223838	2001
14	Significance of c-erbB-2 expression in normal and neoplastic epithelium of biliary tract. ⁵³ ⁶²	Chow NH...Su WC	7645925	1995
15	Serum levels of c-erbB-2 protein in digestive diseases. ⁵³ ⁶²	Motoo Y...Makino H	7528080	1994
16	A prospective multicenter phase II study of FOLFIRINOX as a first-line treatment for patients with advanced and recurrent biliary tract cancer. ⁶²	Takahara N...Koike K	36459291	2022
17	Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study. ⁶²	Meric-Bernstam F...Lee KW	36400106	2022
18	Correlation between efficacy endpoints in patients with advanced biliary tract cancer treated by systemic second-line therapies: Analysis of aggregated data from a systematic literature review. ⁶²	Neuzillet C...Vernerey D	35988887	2022
19	The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer. ⁶²	Berchuck JE...Goyal L	36089135	2022
20	Blood-based tumor fibrosis markers as diagnostic and prognostic biomarkers in patients with biliary tract cancer. ⁶²	Christensen TD...Willumsen N	36455598	2022
21	Natural Language Processing for Automated Classification of Qualitative Data From Interviews of Patients With Cancer. ⁶²	Fang C...Rueda JD	35840523	2022
22	A rapid and sensitive ultra-performance liquid chromatography tandem mass spectrometry method for determination of anlotinib in plasma and dried blood spots: Method development, validation, and clinical application. ⁶²	Zhang J...Tian X	35918299	2022
23	Determination of temporal reproducibility and variability of cancer biomarkers in serum and EDTA plasma samples using a proximity extension assay. ⁶²	Christensen TD...Johansen JS	36376783	2022
24	Phosphoproteomics revealed cellular signals immediately responding to disruption of cancer amino acid homeostasis induced by inhibition of L-type amino acid transporter 1. ⁶²	Okanishi H...Kanai Y	36357940	2022
25	Use, response and outcomes of second-line chemotherapy in patients with advanced biliary tract cancers. ⁶²	Mathers B...Ho C	36320173	2022
26	Feasibility and tolerability of sintilimab plus anlotinib as the second-line therapy for patients with advanced biliary tract cancers: An open-label, single-arm, phase II clinical trial. ⁶²	Jin S...Zong H	36444498	2022
27	Cancer risk according to alcohol consumption trajectories: A population-based cohort study on 2.8 million Korean men. ⁶²	Bui TT...Oh JK	36436924	2022
28	Expert consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the determination of biomarkers in pancreatic and biliary tract cancer. ⁶²	Vera R...Madrigal-Rubiales B	36008616	2022
29	Capecitabine: Still a Standard Option in the Adjuvant Setting of Biliary Tract Cancer? ⁶²	Edeline J...Malka D	35786978	2022
30	Biomarker analysis from a phase II multi-institutional study of nivolumab in patients with advanced refractory biliary tract cancer. ⁶²	Kim DW...Kim RD	36252287	2022
31	Preoperative controlling nutritional status score predicts systemic disease recurrence in patients with resectable biliary tract cancer. ⁶²	Mito M...Wakai T	36404251	2022
32	Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. ⁶²	Vogel A...ESMO Guidelines Committee	36372281	2022
33	Average treatment effect of facility hepatopancreatobiliary malignancy case volume on survival of patients with nonoperatively managed hepatobiliary malignancies. ⁶²	Elshami M...Ocuin LM	36402613	2022
34	Gallbladder Cancer: Current Multimodality Treatment Concepts and Future Directions. ⁶²	Sturm N...Ettrich TJ	36428670	2022
35	Curative surgical resection for initially unresectable metastatic gallbladder cancer following neoadjuvant chemotherapy: Case report and review of literature. ⁶²	Al Jaber F...AlQahtani M	36242892	2022
36	Population pharmacokinetics of zanidatamab, an anti-HER2 biparatopic antibody, in patients with advanced or metastatic cancer. ⁶²	Proctor JR...Davies RH	36102999	2022
37	Light-to-Moderate Alcohol Consumption Increases the Risk of Biliary Tract Cancer in Prediabetes and Diabetes, but Not in Normoglycemic Status: A Nationwide Cohort Study. ⁶²	Park JH...Park JO	35696635	2022
38	Novel parameter for cancer chemosensitivity to fibroblast growth factor receptor inhibitors. ⁶²	Kitano S...Taketo MM	35950366	2022
39	Abdominal aortic calcification volume (AACV) is a predictive factor for postoperative complications associated with biliary tract cancer. ⁶²	Watanabe A...Shirabe K	36447077	2022
40	Epidemiologic patterns of biliary tract cancer in the United States: 2001-2015. ⁶²	Koshiol J...Shroff RT	36384474	2022
41	Advances in Targeted Immunotherapy for Hepatobiliary Cancers. ⁶²	Ruff SM...Pawlik TM	36430440	2022
42	Age trends in biliary tract cancer incidence by anatomical subtype: A Swedish cohort study. ⁶²	Rahman R...Radkiewicz C	36174301	2022
43	Randomised, Phase II study of selumetinib, an oral inhibitor of MEK, in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer. ⁶²	Doherty MK...Knox JJ	35869145	2022
44	Associations between cigarette smoking and biliary tract cancer by anatomic subsite and sex: a prospective cohort study in Japan. ⁶²	Lin Y...JACC Study Group	36030296	2022
45	Characteristic submucosal alteration in biliary carcinogenesis of pancreaticobiliary maljunction with a focus on inflammasome activation. ⁶²	Yamashita S...Shimada M	36259178	2022
46	Disitamab vedotin, a novel HER2-directed antibody-drug conjugate in gastric cancer and other solid tumors. ⁶²	Hu Y...Zhang W	36305543	2022
47	A case of metachronous intraductal tubulopapillary carcinoma of the pancreas after surgery for gallbladder cancer-accompanied pancreaticobiliary maljunction. ⁶²	Kato H...Horiguchi A	35900671	2022
48	Micro-lymph node metastasis in intrahepatic cholangiocarcinoma showing pathological complete response to primary tumor and intrahepatic metastasis treated by gemcitabine plus cisplatin chemotherapy and radical surgery. ⁶²	Shibata Y...Takahashi S	36239900	2022
49	Clinical Implications of BRCA Mutations in Advanced Biliary Tract Cancer. ⁶²	Kim H...Park KU	36257294	2022
50	Gallstones and risk of cancers of the liver, biliary tract and pancreas: a prospective study within two U.S. cohorts. ⁶²	Luo X...Zhang X	35715632	2022

Sources

Genes for Biliary Tract Cancer

Genes related to Biliary Tract Cancer (0 elite genes):

(show top 50) (show all 74)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	SMAD4	SMAD Family Member 4	Protein Coding	22.09	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	12168833 15014009 17470130
2	EGFR	Epidermal Growth Factor Receptor	Protein Coding	21.52	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	16926628 19509244 19777609 (more) 8822109 16809731 15892172 17708250 17150109 17979600
3	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	21.03	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	16926628 19777609 16739351 (more) 17150109 7528080 7645925 15892172 18159174
4	MUC4	Mucin 4, Cell Surface Associated	Protein Coding	20.12	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	18475301
5	MLH1	MutL Homolog 1	Protein Coding	19.23	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	17465213 11223838
6	MET	MET Proto-Oncogene, Receptor Tyrosine Kinase	Protein Coding	18.97	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	10425302 18159174 15892172
7	TGFBR2	Transforming Growth Factor Beta Receptor 2	Protein Coding	18.45	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	12374683 17470130
8	DPYD	Dihydropyrimidine Dehydrogenase	Protein Coding	16.63	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	16820886 19571608
9	MUC5AC	Mucin 5AC, Oligomeric Mucus/Gel-Forming	Protein Coding	14.37	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
10	IL6	Interleukin 6	Protein Coding	13.85	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
11	MTOR	Mechanistic Target Of Rapamycin Kinase	Protein Coding	13.76	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
12	PTGS2	Prostaglandin-Endoperoxide Synthase 2	Protein Coding	13.59	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
13	RUNX3	RUNX Family Transcription Factor 3	Protein Coding	12.44	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
14	LGR4	Leucine Rich Repeat Containing G Protein-Coupled Receptor 4	Protein Coding	12.34	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
15	HDAC9	Histone Deacetylase 9	Protein Coding	11.06	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
16	MIR143	MicroRNA 143	RNA Gene	10.73	DISEASES inferred ¹⁴ ¹⁴
17	MTAP	Methylthioadenosine Phosphorylase	Protein Coding	10.72	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	16373701 15662124
18	MIR145	MicroRNA 145	RNA Gene	10.45	DISEASES inferred ¹⁴ ¹⁴
19	MIR21	MicroRNA 21	RNA Gene	10.28	DISEASES inferred ¹⁴ ¹⁴
20	MIR17	MicroRNA 17	RNA Gene	10.22	DISEASES inferred ¹⁴ ¹⁴
21	MIR199A1	MicroRNA 199a-1	RNA Gene	9.73	DISEASES inferred ¹⁴ ¹⁴
22	MIR29C	MicroRNA 29c	RNA Gene	9.56	DISEASES inferred ¹⁴ ¹⁴
23	MIR214	MicroRNA 214	RNA Gene	9.44	DISEASES inferred ¹⁴ ¹⁴
24	MIR142	MicroRNA 142	RNA Gene	9.36	DISEASES inferred ¹⁴ ¹⁴
25	MIR125A	MicroRNA 125a	RNA Gene	9.36	DISEASES inferred ¹⁴ ¹⁴
26	MIR196A1	MicroRNA 196a-1	RNA Gene	9.24	DISEASES inferred ¹⁴ ¹⁴
27	MIR9-1	MicroRNA 9-1	RNA Gene	9.22	DISEASES inferred ¹⁴ ¹⁴
28	MIR30A	MicroRNA 30a	RNA Gene	9.1	DISEASES inferred ¹⁴ ¹⁴
29	MIR221	MicroRNA 221	RNA Gene	9.1	DISEASES inferred ¹⁴ ¹⁴
30	MIR140	MicroRNA 140	RNA Gene	9.03	DISEASES inferred ¹⁴ ¹⁴
31	MIR204	MicroRNA 204	RNA Gene	9.01	DISEASES inferred ¹⁴ ¹⁴
32	CDR1-AS	CDR1 Antisense RNA	RNA Gene	8.97	DISEASES inferred ¹⁴ ¹⁴
33	MIR150	MicroRNA 150	RNA Gene	8.96	DISEASES inferred ¹⁴ ¹⁴
34	MIR126	MicroRNA 126	RNA Gene	8.94	DISEASES inferred ¹⁴ ¹⁴
35	MIR324	MicroRNA 324	RNA Gene	8.85	DISEASES inferred ¹⁴ ¹⁴
36	MIR31	MicroRNA 31	RNA Gene	8.85	DISEASES inferred ¹⁴ ¹⁴
37	MIR193A	MicroRNA 193a	RNA Gene	8.81	DISEASES inferred ¹⁴ ¹⁴
38	MIR139	MicroRNA 139	RNA Gene	8.78	DISEASES inferred ¹⁴ ¹⁴
39	H2AC18	H2A Clustered Histone 18	Protein Coding	8.74	DISEASES inferred ¹⁴ ¹⁴
40	MIR483	MicroRNA 483	RNA Gene	8.73	DISEASES inferred ¹⁴ ¹⁴
41	MIR29A	MicroRNA 29a	RNA Gene	8.73	DISEASES inferred ¹⁴ ¹⁴
42	MIR25	MicroRNA 25	RNA Gene	8.72	DISEASES inferred ¹⁴ ¹⁴
43	MIR590	MicroRNA 590	RNA Gene	8.71	DISEASES inferred ¹⁴ ¹⁴
44	MIR486-1	MicroRNA 486-1	RNA Gene	8.69	DISEASES inferred ¹⁴ ¹⁴
45	MIR338	MicroRNA 338	RNA Gene	8.67	DISEASES inferred ¹⁴ ¹⁴
46	MIR30E	MicroRNA 30e	RNA Gene	8.59	DISEASES inferred ¹⁴ ¹⁴
47	MIR373	MicroRNA 373	RNA Gene	8.54	DISEASES inferred ¹⁴ ¹⁴
48	MIR149	MicroRNA 149	RNA Gene	8.51	DISEASES inferred ¹⁴ ¹⁴
49	MIR181A1	MicroRNA 181a-1	RNA Gene	8.44	DISEASES inferred ¹⁴ ¹⁴
50	MIR424	MicroRNA 424	RNA Gene	8.42	DISEASES inferred ¹⁴ ¹⁴

Sources

Variations for Biliary Tract Cancer

Sources

Expression for Biliary Tract Cancer

Search GEO for disease gene expression data for Biliary Tract Cancer.

Sources

Pathways for Biliary Tract Cancer

Pathways related to Biliary Tract Cancer according to GeneCards Suite gene sharing:

(show all 34)

#	Super pathways	Score	Top Affiliating Genes
1	Signal Transduction ⁶⁶	13.67	TGFBR2 SMAD4 RUNX3 MTOR MET LGR4
2	GPCR Pathway ⁶⁴ Show member pathways Breast Cancer Regulation by Stathmin1 ⁶⁴ Estrogen Pathway ⁶⁴ NFAT in Immune Response ⁶⁴ P2Y Receptor Signaling ⁶⁴ Pancreatic Adenocarcinoma ⁶⁴ Paxillin Interactions ⁶⁴ Ras Pathway ⁶⁴	13.63	TGFBR2 SMAD4 PTGS2 MET IL6 HDAC9
3	Disease ⁶⁶ Show member pathways Infectious disease ⁶⁶	13.63	TGFBR2 SMAD4 MUC5AC MUC4 MTOR MLH1
4	MIF Mediated Glucocorticoid Regulation ⁶⁴ Show member pathways all-trans-Retinoic Acid Signaling in Brain ⁶⁴ Endothelin-1 Signaling Pathway ⁶⁴ Glucocorticoid Receptor Signaling ⁶⁴ IL-6 Pathway ⁶⁴ MIF Regulation of Innate Immune Cells ⁶⁴ NFAT Signaling and Lymphocyte Interactions ⁶⁴ Overview of proinflammatory and profibrotic mediators ⁷⁴ PEDF Induced Signaling ⁶⁴ PGC1Alpha Pathway ⁶⁴ RAR-Gamma-RXR-Alpha Degradation ⁶⁴ STAT3 Pathway ⁶⁴	13.55	SMAD4 PTGS2 MTOR MET IL6 HDAC9
5	RAF/MAP kinase cascade ⁶⁶ Show member pathways Diseases of signal transduction by growth factor receptors and second messengers ⁶⁶ MAPK family signaling cascades ⁶⁶ MAPK1/MAPK3 signaling ⁶⁶	13.25	TGFBR2 SMAD4 MTOR MET IL6 HDAC9
6	NFAT and Cardiac Hypertrophy ⁶⁴ Show member pathways IGF1R Signaling ⁶⁴ Signaling Involved in Cardiac Hypertrophy ⁶⁴	12.75	TGFBR2 MTOR IL6 HDAC9 ERBB2 EGFR
7	Endometrial cancer ⁷⁴ Show member pathways Chromosomal and microsatellite instability in colorectal cancer ⁷⁴ Melanoma ⁷⁴ Non-small cell lung cancer ⁷⁴ Pancreatic adenocarcinoma pathway ⁷⁴ Signal transduction PTEN pathway ²²	12.42	TGFBR2 SMAD4 PTGS2 MTOR MLH1 ERBB2
8	Breast cancer pathway ⁷⁴ Show member pathways Embryonic stem cell pluripotency pathways ⁷⁴	12.37	SMAD4 MTOR ERBB2 EGFR
9	NF-kappaB Pathway ⁷⁰ Show member pathways Akt Pathway ⁷⁰ Apoptosis Pathway ⁷⁰	12.31	EGFR ERBB2 MET MTOR TGFBR2
10	G-protein signaling RAC1 in cellular process ²² Show member pathways CDC42 signaling events ⁶¹ Cytoskeleton remodeling CDC42 in cellular processes ²² RAC1 signaling pathway ⁶¹	12.29	MTOR MET IL6 ERBB2 EGFR
11	MAPK Signaling: Mitogens ⁶⁵ Show member pathways Akt Signaling Pathway ⁶⁵	12.15	MTOR MET ERBB2 EGFR
12	Integrated breast cancer pathway ⁷⁴	12.05	TGFBR2 SMAD4 MTOR EGFR
13	Transcription Androgen Receptor nuclear signaling ²² Show member pathways Translation Non-genomic (rapid) action of Androgen Receptor ²²	11.93	TGFBR2 MTOR IL6 ERBB2 EGFR
14	mTOR Signaling ⁶⁵	11.86	MTOR MET LGR4 ERBB2 EGFR
15	p53 transcriptional gene network ⁷⁴	11.81	MTOR MLH1 MIR145
16	Cytokine production by Th17 cells in CF (Mouse model) ²² Show member pathways Cytokine production by Th17 cells in CF ²²	11.8	TGFBR2 SMAD4 IL6
17	Th17 Differentiation ⁶⁵ Show member pathways IL-21 Signaling and its Primary Biological Effects in Different Immune Cell Types ⁶⁵	11.78	TGFBR2 SMAD4 IL6
18	Hippo-Merlin signaling dysregulation ⁷⁴ Show member pathways Hippo signaling regulation pathways ⁷⁴	11.78	MTOR MET EGFR
19	TGF-beta Signaling Pathways ⁶⁵	11.76	TGFBR2 SMAD4 RUNX3 MTOR
20	Clock-controlled autophagy in bone metabolism ⁷⁴	11.71	SMAD4 MTOR IL6
21	Cell differentiation - expanded index ⁷⁴ Show member pathways Cell differentiation - index ⁷⁴	11.69	MIR17 MIR145 MIR143
22	Colorectal Cancer Metastasis ⁶⁴	11.65	TGFBR2 SMAD4 PTGS2 MLH1 IL6 EGFR
23	Development_TGF-beta receptor signaling ²²	11.64	TGFBR2 SMAD4 ERBB2
24	miRNAs involvement in the immune response in sepsis ⁷⁴	11.57	MIR21 MIR145 IL6
25	miRNAs involved in DNA damage response ⁷⁴	11.56	MIR143 MIR145 MIR17 MIR21
26	Hepatitis C and hepatocellular carcinoma ⁷⁴	11.51	SMAD4 PTGS2 IL6
27	IL-2 Gene Expression in Activated and Quiescent T-Cells ⁶⁴ Show member pathways TOB in T-Cell Signaling ⁶⁴	11.5	TGFBR2 SMAD4 ERBB2 EGFR
28	Hair follicle development: cytodifferentiation - part 3 of 3 ⁷⁴	11.49	SMAD4 RUNX3 EGFR
29	NRP1-triggered signaling pathways in pancreatic cancer ⁷⁴	11.43	TGFBR2 SMAD4 MET EGFR
30	Heart development ⁷⁴	11.42	SMAD4 MIR145 MIR143
31	Head and neck squamous cell carcinoma ⁷⁴	11.42	TGFBR2 SMAD4 MTOR ERBB2 EGFR
32	a6b1 and a6b4 Integrin signaling ⁶¹	11.29	EGFR ERBB2 MET
33	Relationship between inflammation, COX-2 and EGFR ⁷⁴	10.62	EGFR PTGS2
34	Extracellular vesicle-mediated signaling in recipient cells ⁷⁴	10.47	SMAD4 MTOR MET ERBB2 EGFR

Sources

GO Terms for Biliary Tract Cancer

Cellular components related to Biliary Tract Cancer according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	basal plasma membrane	GO:0009925	9.1	MET ERBB2 EGFR

Biological processes related to Biliary Tract Cancer according to GeneCards Suite gene sharing:

(show all 20)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of cell population proliferation	GO:0008284	10.29	TGFBR2 PTGS2 MIR21 IL6 ERBB2 EGFR
2	negative regulation of apoptotic process	GO:0043066	10.24	PTGS2 MTOR MIR21 IL6 ERBB2 EGFR
3	positive regulation of protein kinase B signaling	GO:0051897	9.99	MIR21 MIR143 MET EGFR
4	embryo implantation	GO:0007566	9.96	TGFBR2 PTGS2 MIR21
5	regulation of ERK1 and ERK2 cascade	GO:0070372	9.85	MIR145 ERBB2 EGFR
6	activation of protein kinase B activity	GO:0032148	9.78	MTOR MIR21 MIR143
7	negative regulation of interleukin-1-mediated signaling pathway	GO:2000660	9.74	IL6 MIR21
8	positive regulation of cytokine production involved in inflammatory response	GO:1900017	9.73	MIR21 MIR17 IL6
9	regulation of cell population proliferation	GO:0042127	9.73	EGFR ERBB2 PTGS2 SMAD4 TGFBR2
10	negative regulation of hydrogen peroxide-mediated programmed cell death	GO:1901299	9.67	MET MIR21
11	positive regulation of miRNA maturation	GO:1903800	9.58	IL6 EGFR
12	negative regulation of vascular associated smooth muscle cell apoptotic process	GO:1905460	9.55	MIR21 MIR17
13	aorta smooth muscle tissue morphogenesis	GO:0060414	9.54	MIR145 MIR143
14	positive regulation of metalloendopeptidase activity	GO:1904685	9.52	MIR21 MIR17
15	negative regulation of cardiac muscle hypertrophy	GO:0010614	9.46	SMAD4 MIR21 MIR145
16	regulation of phenotypic switching	GO:1900239	9.4	MIR145 MIR143
17	positive regulation of pulmonary blood vessel remodeling	GO:1905111	9.37	MIR17 MIR143
18	positive regulation of cellular response to hypoxia	GO:1900039	9.32	MIR21 MIR145
19	positive regulation of epithelial to mesenchymal transition	GO:0010718	9.28	TGFBR2 SMAD4 MTOR MIR21 IL6
20	establishment or maintenance of cell type involved in phenotypic switching	GO:0044663	8.96	MIR145 MIR143